866-997-4948(US-Canada Toll Free)

Head And Neck Cancer - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 1247 Pages

Head And Neck Cancer - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer - Pipeline Review, H1 2017, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape.

Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 87, 98, 5, 92, 17 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 11, 6, 1, 15 and 3 molecules, respectively.

Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 9
Head And Neck Cancer - Overview 10
Head And Neck Cancer - Therapeutics Development 11
Head And Neck Cancer - Therapeutics Assessment 51
Head And Neck Cancer - Companies Involved in Therapeutics Development 75
Head And Neck Cancer - Drug Profiles 167
Head And Neck Cancer - Dormant Projects 1190
Head And Neck Cancer - Discontinued Products 1200
Head And Neck Cancer - Product Development Milestones 1202
Appendix 1211

List of Tables
Number of Products under Development for Head And Neck Cancer, H1 2017 46
Number of Products under Development by Companies, H1 2017 48
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 49
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 50
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 51
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 52
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 53
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 54
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 55
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017 56
Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017 57
Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017 58
Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017 59
Number of Products under Development by Universities/Institutes, H1 2017 60
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 62
Products under Development by Companies, H1 2017 63
Products under Development by Companies, H1 2017 (Contd..1), H1 2017 64
Products under Development by Companies, H1 2017 (Contd..2), H1 2017 65
Products under Development by Companies, H1 2017 (Contd..3), H1 2017 66
Products under Development by Companies, H1 2017 (Contd..4), H1 2017 67
Products under Development by Companies, H1 2017 (Contd..5), H1 2017 68
Products under Development by Companies, H1 2017 (Contd..6), H1 2017 69
Products under Development by Companies, H1 2017 (Contd..7), H1 2017 70
Products under Development by Companies, H1 2017 (Contd..8), H1 2017 71
Products under Development by Companies, H1 2017 (Contd..9), H1 2017 72
Products under Development by Companies, H1 2017 (Contd..10), H1 2017 73
Products under Development by Companies, H1 2017 (Contd..11), H1 2017 74
Products under Development by Companies, H1 2017 (Contd..12), H1 2017 75
Products under Development by Companies, H1 2017 (Contd..13), H1 2017 76
Products under Development by Companies, H1 2017 (Contd..14), H1 2017 77
Products under Development by Companies, H1 2017 (Contd..15), H1 2017 78
Products under Development by Companies, H1 2017 (Contd..16), H1 2017 79
Products under Development by Companies, H1 2017 (Contd..17), H1 2017 80
Products under Development by Companies, H1 2017 (Contd..18), H1 2017 81
Products under Development by Companies, H1 2017 (Contd..19), H1 2017 82
Products under Development by Universities/Institutes, H1 2017 83
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 84
Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 85
Number of Products by Stage and Target, H1 2017 87
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 88
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 89
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 90
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 91
Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017 92
Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017 93
Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017 94
Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017 95
Number of Products by Stage and Mechanism of Action, H1 2017 97
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 98
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 99
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 100
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 101
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017 102
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017 103
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017 104
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017 105
Number of Products by Stage and Route of Administration, H1 2017 107
Number of Products by Stage and Molecule Type, H1 2017 109
Head And Neck Cancer - Pipeline by 3SBio Inc, H1 2017 110
Head And Neck Cancer - Pipeline by 4SC AG, H1 2017 110
Head And Neck Cancer - Pipeline by AB Science SA, H1 2017 111
Head And Neck Cancer - Pipeline by AbbVie Inc, H1 2017 111
Head And Neck Cancer - Pipeline by Abion Inc, H1 2017 112
Head And Neck Cancer - Pipeline by Accelerated Pharma Inc, H1 2017 112
Head And Neck Cancer - Pipeline by Acceleron Pharma Inc, H1 2017 113
Head And Neck Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2017 113
Head And Neck Cancer - Pipeline by Aduro BioTech Inc, H1 2017 114
Head And Neck Cancer - Pipeline by Advaxis Inc, H1 2017 114
Head And Neck Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017 115
Head And Neck Cancer - Pipeline by Affimed GmbH, H1 2017 115
Head And Neck Cancer - Pipeline by Altor BioScience Corp, H1 2017 116
Head And Neck Cancer - Pipeline by Ambrx Inc, H1 2017 116
Head And Neck Cancer - Pipeline by amcure GmbH, H1 2017 117
Head And Neck Cancer - Pipeline by Amgen Inc, H1 2017 117
Head And Neck Cancer - Pipeline by arGEN-X BV, H1 2017 118
Head And Neck Cancer - Pipeline by ArQule Inc, H1 2017 118
Head And Neck Cancer - Pipeline by Array BioPharma Inc, H1 2017 119
Head And Neck Cancer - Pipeline by Aspyrian Therapeutics Inc, H1 2017 119
Head And Neck Cancer - Pipeline by Astellas Pharma Inc, H1 2017 120
Head And Neck Cancer - Pipeline by AstraZeneca Plc, H1 2017 121
Head And Neck Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2017 122
Head And Neck Cancer - Pipeline by ATLAB Pharma SAS, H1 2017 122
Head And Neck Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017 123
Head And Neck Cancer - Pipeline by Bayer AG, H1 2017 124
Head And Neck Cancer - Pipeline by BeiGene Ltd, H1 2017 124
Head And Neck Cancer - Pipeline by Benitec Biopharma Ltd, H1 2017 125
Head And Neck Cancer - Pipeline by Beta Pharma Inc, H1 2017 125
Head And Neck Cancer - Pipeline by Bexion Pharmaceuticals LLC, H1 2017 126
Head And Neck Cancer - Pipeline by BioDiem Ltd, H1 2017 126
Head And Neck Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H1 2017 127
Head And Neck Cancer - Pipeline by Bionovis SA, H1 2017 127
Head And Neck Cancer - Pipeline by BioNTech AG, H1 2017 128
Head And Neck Cancer - Pipeline by Biotest AG, H1 2017 128
Head And Neck Cancer - Pipeline by Biothera Pharmaceutical Inc, H1 2017 129
Head And Neck Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017 129
Head And Neck Cancer - Pipeline by Boston Biomedical Inc, H1 2017 130
Head And Neck Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017 130
Head And Neck Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017 131
Head And Neck Cancer - Pipeline by Celgene Corp, H1 2017 131
Head And Neck Cancer - Pipeline by Cell Medica Ltd, H1 2017 132
Head And Neck Cancer - Pipeline by Cellceutix Corp, H1 2017 132
Head And Neck Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017 133
Head And Neck Cancer - Pipeline by Celprogen Inc, H1 2017 133
Head And Neck Cancer - Pipeline by Centrose LLC, H1 2017 134
Head And Neck Cancer - Pipeline by Corvus Pharmaceuticals Inc, H1 2017 134
Head And Neck Cancer - Pipeline by Cristal Therapeutics BV, H1 2017 135
Head And Neck Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017 135
Head And Neck Cancer - Pipeline by CytImmune Sciences Inc, H1 2017 136
Head And Neck Cancer - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 136
Head And Neck Cancer - Pipeline by Denceptor Therapeutics Ltd, H1 2017 137
Head And Neck Cancer - Pipeline by DNJ Pharma Inc, H1 2017 137
Head And Neck Cancer - Pipeline by Dynavax Technologies Corp, H1 2017 138
Head And Neck Cancer - Pipeline by Eisai Co Ltd, H1 2017 138
Head And Neck Cancer - Pipeline by Eleven Biotherapeutics Inc, H1 2017 139
Head And Neck Cancer - Pipeline by Eli Lilly and Company, H1 2017 139
Head And Neck Cancer - Pipeline by Etubics Corp, H1 2017 140
Head And Neck Cancer - Pipeline by Eureka Therapeutics Inc, H1 2017 140
Head And Neck Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 141
Head And Neck Cancer - Pipeline by Five Prime Therapeutics Inc, H1 2017 141
Head And Neck Cancer - Pipeline by Forty Seven Inc, H1 2017 142
Head And Neck Cancer - Pipeline by Fujifilm Corp, H1 2017 142
Head And Neck Cancer - Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2017 143
Head And Neck Cancer - Pipeline by Galectin Therapeutics Inc, H1 2017 143
Head And Neck Cancer - Pipeline by Genelux Corp, H1 2017 144
Head And Neck Cancer - Pipeline by GeneSegues Inc, H1 2017 144
Head And Neck Cancer - Pipeline by Genexine Inc, H1 2017 145
Head And Neck Cancer - Pipeline by Genmab A/S, H1 2017 145
Head And Neck Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017 146
Head And Neck Cancer - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017 147
Head And Neck Cancer - Pipeline by Gliknik Inc, H1 2017 147
Head And Neck Cancer - Pipeline by Glycotope GmbH, H1 2017 148
Head And Neck Cancer - Pipeline by Griffith University, H1 2017 148
Head And Neck Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017 149
Head And Neck Cancer - Pipeline by Hookipa Biotech AG, H1 2017 149
Head And Neck Cancer - Pipeline by Horizon Pharma Plc, H1 2017 150
Head And Neck Cancer - Pipeline by Hutchison China MediTech Ltd, H1 2017 150
Head And Neck Cancer - Pipeline by Ignyta Inc, H1 2017 151
Head And Neck Cancer - Pipeline by Immunocore Ltd, H1 2017 151
Head And Neck Cancer - Pipeline by Immunomedics Inc, H1 2017 152
Head And Neck Cancer - Pipeline by Immunovaccine Inc, H1 2017 152
Head And Neck Cancer - Pipeline by Immunovative Therapies Ltd, H1 2017 153
Head And Neck Cancer - Pipeline by Incyte Corp, H1 2017 153
Head And Neck Cancer - Pipeline by Infinity Pharmaceuticals Inc, H1 2017 154
Head And Neck Cancer - Pipeline by Innate Pharma SA, H1 2017 154
Head And Neck Cancer - Pipeline by Inovio Pharmaceuticals Inc, H1 2017 155
Head And Neck Cancer - Pipeline by InteRNA Technologies BV, H1 2017 155
Head And Neck Cancer - Pipeline by Ipsen SA, H1 2017 156
Head And Neck Cancer - Pipeline by IRX Therapeutics Inc, H1 2017 156
Head And Neck Cancer - Pipeline by ISA Pharmaceuticals BV, H1 2017 157
Head And Neck Cancer - Pipeline by ISU ABXIS Co Ltd, H1 2017 157
Head And Neck Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 158
Head And Neck Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017 158
Head And Neck Cancer - Pipeline by Johnson & Johnson, H1 2017 159
Head And Neck Cancer - Pipeline by Juno Therapeutics Inc, H1 2017 159
Head And Neck Cancer - Pipeline by Kite Pharma Inc, H1 2017 160
Head And Neck Cancer - Pipeline by Kura Oncology Inc, H1 2017 160
Head And Neck Cancer - Pipeline by Laboratoires Pierre Fabre SA, H1 2017 161
Head And Neck Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017 161
Head And Neck Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017 162
Head And Neck Cancer - Pipeline by Loxo Oncology Inc, H1 2017 162
Head And Neck Cancer - Pipeline by Lytix Biopharma AS, H1 2017 163
Head And Neck Cancer - Pipeline by Mabion SA, H1 2017 163
Head And Neck Cancer - Pipeline by MacroGenics Inc, H1 2017 164
Head And Neck Cancer - Pipeline by Marsala Biotech Inc, H1 2017 164
Head And Neck Cancer - Pipeline by Mateon Therapeutics Inc, H1 2017 165
Head And Neck Cancer - Pipeline by MaxiVAX SA, H1 2017 165
Head And Neck Cancer - Pipeline by Meabco A/S, H1 2017 166
Head And Neck Cancer - Pipeline by MedImmune LLC, H1 2017 167
Head And Neck Cancer - Pipeline by Merck & Co Inc, H1 2017 168
Head And Neck Cancer - Pipeline by Merck KGaA, H1 2017 169
Head And Neck Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 169
Head And Neck Cancer - Pipeline by Mirati Therapeutics Inc, H1 2017 170
Head And Neck Cancer - Pipeline by Moleculin Biotech Inc, H1 2017 170
Head And Neck Cancer - Pipeline by Molplex Ltd, H1 2017 171
Head And Neck Cancer - Pipeline by NanoCarrier Co Ltd, H1 2017 171
Head And Neck Cancer - Pipeline by NantKwest Inc, H1 2017 172
Head And Neck Cancer - Pipeline by Natco Pharma Ltd, H1 2017 172
Head And Neck Cancer - Pipeline by NeoImmuneTech Inc, H1 2017 173
Head And Neck Cancer - Pipeline by Neonc Technologies Inc, H1 2017 173
Head And Neck Cancer - Pipeline by Neumedicines Inc, H1 2017 174
Head And Neck Cancer - Pipeline by Northwest Biotherapeutics Inc, H1 2017 174
Head And Neck Cancer - Pipeline by Novartis AG, H1 2017 175
Head And Neck Cancer - Pipeline by Noxopharm Ltd, H1 2017 175
Head And Neck Cancer - Pipeline by Oncobiologics Inc, H1 2017 176
Head And Neck Cancer - Pipeline by Oncolys BioPharma Inc, H1 2017 176
Head And Neck Cancer - Pipeline by Onconova Therapeutics Inc, H1 2017 177

List of Figures
Number of Products under Development for Head And Neck Cancer, H1 2017 46
Number of Products under Development by Companies, H1 2017 47
Number of Products under Development by Universities/Institutes, H1 2017 60
Number of Products by Top 10 Targets, H1 2017 86
Number of Products by Stage and Top 10 Targets, H1 2017 86
Number of Products by Top 10 Mechanism of Actions, H1 2017 96
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 96
Number of Products by Top 10 Routes of Administration, H1 2017 106
Number of Products by Stage and Top 10 Routes of Administration, H1 2017 106
Number of Products by Top 10 Molecule Types, H1 2017 108
Number of Products by Stage and Top 10 Molecule Types, H1 2017 108

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *